EOLS News and Press, Evolus Inc. From 03/03/22

Evolus press release (NASDAQ:EOLS): Q4 GAAP EPS of -$0.33 beats by $0.07. Revenue of $34.7M (+68.6% Y/Y) misses by $0.07M. For further details see: Evolus GAAP EPS of -$0.33 beats by $0.07, revenue of $34.7M misses by $0.07M

Evolus (NASDAQ:EOLS) said Lauren Silvernail will retire from her role as CFO and EVP of corporate development effective May 31, after nearly 4 years with the company. The search for her successor is already underway. Most recently, Silvernail and team successfully negotiated a $125M...

Q4 2021 Net Revenue of $34.7 Million, Up 68% from Q4 2020 Full-Year 2021 Net Revenue of $99.7 Million, Up 76% Over 2020 Full-Year 2022 Net Revenue Guidance of $143 to $150 Million Reaffirmed Cash Position at December 31, 2021 of $146.3 Million Evo...

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that after nearly four years with the company, Lauren Silvernail will retire from her position as Chief Financial Officer and Executive...

ACR, AQN, AVAV, AVGO, BCEL, CEMI, CLLS, CLXT, COO, COST, OTCPK:CURLF, DBVT, DUOL, EGLE, ENVX, EOLS, ESTC, EVFM, FCRD, FDUS, FNKO, GPS, INMB, OTCPK:MEGEF, MRVL, NCMI, ONCY, PAYO, PBYI, SIGA, SWBI, VERI, VZIO For Seeking Alpha's full earnings season calendar, click here. For further details s...

Inducement Grant Reported Under Nasdaq Listing Rule 5635(c)(4) Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, has appointed Christos Monovoukas as Senior Vice President, Corporate Develo...

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that it will report its fourth quarter and year end 2021 financial results and provide a business update on Thursday, March 3, 2022, af...

Evolus (EOLS) announced on Tuesday that the Australian Therapeutics Good Administration (TGA) accepted its submission seeking the regulatory approval of Nuceiva. The company expects to receive the full TGA clearance for Nuceiva in 2023.  “We look forward to completing the necessar...

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company, today announced the acceptance of its submission to the Australian Therapeutics Good Administration (TGA) for regulatory approval of Nuceiva ® (prabotulinumtoxinA), the first and only neurotoxin dedicated exclusively to...

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in the Virtual 11th Annual SVB Leerink Global Healthcare Conference. An a...